SutroVax raises $64M with plans to challenge Pfizer’s megablockbuster Prevnar 13 for the heavyweight title in vaccines
When SutroVax was spun out of Sutro about four years ago, the biotech took along a conjugation platform that was repurposed for developing a new brand of vaccines. And now that they are aiming for the clinic with a lead pneumococcal vaccine, SutroVax has reeled in a whopping $64 million raise to get them well into human studies for a new vaccine that will challenge the megablockbuster Prevnar 13 for the heavyweight title in its field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.